

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	S.D. Harrison et al.	Attorney Docket No.:	PP19016.003
Application No.:	10/506570	Art Unit:	1614 / Confirmation No.: 1325
Filed:	April 29, 2005	Examiner:	A.A. Lewis
Title:	METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIA		

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING  
REJECTION OVER A PRIOR PATENT

TO THE COMMISSIONER FOR PATENTS:

Novartis Vaccines and Diagnostics, Inc., a Delaware corporation, having a principal place of business at 4560 Horton Street, Emeryville, California 94608-4766, represents that it is the owner of the entire right, title, and interest in the above-identified patent application by a chain of title from the inventors of the above-identified patent application.

The owner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, and as presently shortened by any terminal disclaimer of prior U.S. Patent No. 7,045,519, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to prior U.S. Patent No. 7,045,519, this agreement to run with any patent granted on said above-identified application and to be binding upon the grantee, its successors, or assigns.

The owner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of prior U.S. Patent No. 7,045,519 in the event that said prior U.S. Patent No. 7,045,519 later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is otherwise terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned (whose title is supplied below) is empowered to act on behalf of the organization.

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>SM</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100

Please charge my Deposit Account No. 03-1740 in the amount of \$140 to cover the terminal disclaimer fee under 37 C.F.R. § 1.20(d).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NOVARTIS VACCINES AND  
DIAGNOSTICS, INC.

Date:

February 26, 2009

By:

Dennis K. Shelton

Name: Dennis K. Shelton

Registration No. 26,997

Title: Attorney for Owner

DKS:cj

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>PLC</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100